RxDoctor Payments Data

Amy Meints

Family · Portage, MINPI 1235602434

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 71 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$280
  • Alkermes, Inc.$136
  • AbbVie$133
  • Johnson & Johnson$100
  • Biohaven Pharmaceutical Holding Company Ltd.$84
  • Bayer$83
  • plus $603 from 19 others

What the payments were for

  • Food & beverage$1,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$41,844
Medicare patients
183
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$39,906
TrulicityDulaglutide14$14,865
LinzessLinaclotide21$13,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,873
MyrbetriqMirabegron12$5,741
ArexvyRsvpref3 Antigen/As01e/Pf14$4,253
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,610
MovantikNaloxegol Oxalate15$3,525
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$2,403
Levothyroxine Sodium215$2,179
Humalog Kwikpen U-100Insulin Lispro28$2,148
Aripiprazole25$1,953
Lacosamide16$1,746
Pregabalin26$1,717
Desmopressin Acetate21$1,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$39,90668 claims
Lilly USA, LLCTrulicity$67$14,86514 claims
AbbVieLinzess$133$13,50521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,657 family providers in Michigan.

Other family in Portage

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →